Asad Haider
Stock Analyst at Goldman Sachs
(2.65)
# 2,176
Out of 5,058 analysts
11
Total ratings
80%
Success rate
12.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Buy | $186 → $212 | $200.00 | +6.00% | 2 | Oct 9, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $21.87 | -22.27% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $39.46 | +6.44% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $49.53 | -23.28% | 1 | Sep 12, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Neutral | $27 | $38.91 | -30.61% | 1 | Jul 17, 2025 | |
| BNTX BioNTech SE | Initiates: Neutral | $110 | $102.53 | +7.29% | 1 | May 29, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $1,030.05 | -13.79% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $233.87 | -17.05% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $47.06 | +16.87% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $25.45 | -1.77% | 1 | Apr 8, 2025 |
Johnson & Johnson
Oct 9, 2025
Maintains: Buy
Price Target: $186 → $212
Current: $200.00
Upside: +6.00%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $21.87
Upside: -22.27%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $39.46
Upside: +6.44%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $49.53
Upside: -23.28%
NewAmsterdam Pharma Company
Jul 17, 2025
Initiates: Neutral
Price Target: $27
Current: $38.91
Upside: -30.61%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $102.53
Upside: +7.29%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $1,030.05
Upside: -13.79%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $233.87
Upside: -17.05%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $47.06
Upside: +16.87%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $25.45
Upside: -1.77%